[go: up one dir, main page]

ES2189808T3 - Composiciones de aporte terapeutico y metodos de uso de las mismas. - Google Patents

Composiciones de aporte terapeutico y metodos de uso de las mismas.

Info

Publication number
ES2189808T3
ES2189808T3 ES94931827T ES94931827T ES2189808T3 ES 2189808 T3 ES2189808 T3 ES 2189808T3 ES 94931827 T ES94931827 T ES 94931827T ES 94931827 T ES94931827 T ES 94931827T ES 2189808 T3 ES2189808 T3 ES 2189808T3
Authority
ES
Spain
Prior art keywords
approximately
c2h4o
compositions
methods
c3h6o
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94931827T
Other languages
English (en)
Inventor
R Martin Emanuele
Hameedsulthan S Allaudeen
Konstantin G Kousoulas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LadRx Corp
Original Assignee
CytRx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CytRx Corp filed Critical CytRx Corp
Application granted granted Critical
Publication of ES2189808T3 publication Critical patent/ES2189808T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPOSICIONES Y METODOS PARA EL TRATAMIENTO DE LAS ENFERMEDADES INFECCIOSAS Y LAS AFECCIONES GENETICAS MEDIANTE TERAPIA GENETICA Y A LA LIBERACION INTRACELULAR DE OLIGONUCLEOTIDOS ANTISENTIDO U OTRAS SECUENCIAS DEL ACIDO NUCLEICO. LA PRESENTE INVENCION COMPRENDE UNA COMPOSICION DE LIBERACION TERAPEUTICA EFECTIVA PARA EL TRATAMIENTO DE UN ESTADO PATOLOGICO, QUE COMPRENDE UNA MEZCLA ADMINISTRABLE DE UNA CANTIDAD EFECTIVA DE UN COMPUESTO TERAPEUTICO, CAPAZ DE ALTERAR LA FUNCION DE LA SECUENCIA DEL ACIDO NUCLEICO Y UNA CANTIDAD EFECTIVA DE UN COPOLIMERO DE BLOQUE ANIONICO SUPERFICIACTIVO DE LA SIGUIENTE FORMULA GENERAL: HO(C{SUB,2}H{SUB,4}O){SUB,B}(C{SUB,3}H{SUB,6}O){SUB,A} (C{SUB,2}H{SUB,4}O){SUB,B}H EN DONDE A ES UN NUMERO ENTERO DE MODO QUE EL HIDROFOBO REPRESENTADO POR (C{SUB,3}H{SUB,6}O) TIENE UN PESO MOLECULAR DE APROXIMADAMENTE 750 Y APROXIMADAMENTE 15.000, PREFERENTEMENTE ENTRE APROXIMADAMENTE 2.250 Y APROXIMADAMENTE 15.000, Y AUN MAS DESEABLEMENTE ENTRE APROXIMADAMENTE 3.250 Y APROXIMADAMENTE 15.000, Y B ES UN NUMERO ENTERO DE FORMA QUE LA PORCION HIDROFILA REPRESENTADA POR (C{SUB,2}H{SUB,4}O) CONSTITUYA APROXIMADAMENTE 1% A APROXIMADAMENTE 50% DEL PESO DEL COMPUESTO, Y PREFERENTEMENTE APROXIMADAMENTE DEL 5% DEL PESO A APROXIMADAMENTE EL 20% DEL PESO.
ES94931827T 1993-10-15 1994-10-12 Composiciones de aporte terapeutico y metodos de uso de las mismas. Expired - Lifetime ES2189808T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13827193A 1993-10-15 1993-10-15

Publications (1)

Publication Number Publication Date
ES2189808T3 true ES2189808T3 (es) 2003-07-16

Family

ID=22481270

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94931827T Expired - Lifetime ES2189808T3 (es) 1993-10-15 1994-10-12 Composiciones de aporte terapeutico y metodos de uso de las mismas.

Country Status (9)

Country Link
EP (1) EP0723440B1 (es)
JP (1) JP3819422B2 (es)
KR (1) KR100218140B1 (es)
AT (1) ATE230260T1 (es)
AU (1) AU8076494A (es)
DE (1) DE69431959T2 (es)
DK (1) DK0723440T3 (es)
ES (1) ES2189808T3 (es)
WO (1) WO1995010265A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1181937A3 (en) * 1994-08-09 2004-02-04 Cytrx Corporation Novel vaccine adjuvant and vaccine
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6673914B1 (en) 1998-01-22 2004-01-06 John Wayne Cancer Institute Human tumor-associated gene
KR100360827B1 (ko) * 1999-08-14 2002-11-18 주식회사 삼양사 난용성 약물을 가용화하기 위한 고분자 조성물 및 그의 제조방법
EP1278551A2 (en) 2000-04-21 2003-01-29 Vical Incorporated Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics
EP1232758A1 (fr) * 2001-02-19 2002-08-21 Aventis Pasteur Polynucléotide formulé en vue d'un transfert intracellulaire amélioré
ES2745068T3 (es) 2001-12-20 2020-02-27 Merck Sharp & Dohme Composiciones de SYN3 y métodos
NZ543970A (en) 2003-06-04 2008-09-26 Canji Inc Methods and compositions for interferon therapy
ES2794700T3 (es) 2013-02-05 2020-11-18 Univ Leland Stanford Junior Terapias dirigidas a CD47 para el tratamiento de enfermedades infecciosas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3308458A1 (de) * 1983-03-10 1984-09-13 Behringwerke Ag, 3550 Marburg Verfahren zur adjuvierung von vaccinen
IT1191608B (it) * 1985-02-01 1988-03-23 Zambon Spa Composizione farmaceutica e forme farmaceutiche che la contengono
AU6334586A (en) * 1986-05-15 1987-12-01 Emory University Composition and method for treating a thrombus and embolus
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US5221495A (en) * 1990-04-13 1993-06-22 Colgate-Palmolive Company Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions
DE69230372T2 (de) * 1991-03-19 2000-06-15 Cytrx Corp., Norcross Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität
WO1993008845A1 (en) * 1991-11-08 1993-05-13 Massachusetts Institute Of Technology Localized oligonucleotide therapy

Also Published As

Publication number Publication date
EP0723440A1 (en) 1996-07-31
EP0723440A4 (en) 1997-06-11
WO1995010265A1 (en) 1995-04-20
ATE230260T1 (de) 2003-01-15
JP3819422B2 (ja) 2006-09-06
EP0723440B1 (en) 2003-01-02
KR100218140B1 (ko) 1999-09-01
KR960704534A (ko) 1996-10-09
AU8076494A (en) 1995-05-04
DE69431959T2 (de) 2003-11-06
DE69431959D1 (de) 2003-02-06
DK0723440T3 (da) 2003-02-24
JPH09503788A (ja) 1997-04-15

Similar Documents

Publication Publication Date Title
ES2189808T3 (es) Composiciones de aporte terapeutico y metodos de uso de las mismas.
RU2175337C2 (ru) Полинуклеотидные композиции
EP0653439B1 (de) Stabilisierte Oligonucleotide und deren Verwendung
DE60109916T2 (de) MODULATION EINER OLIGONUKLEOTID- CpG-VERMITTELTEN IMMUNSTIMULATION DURCH POSITIONELLE MODIFIKATION VON NUKLEOSIDEN
Agrawal et al. Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus.
AU783745B2 (en) Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
KR100310277B1 (ko) 뼈 형성 촉진용 저분자량 하이알루론산의 제조
KR950702626A (ko) 치료제로서 자체-안정화된 올리고누클레오티드(self-stabilized loigonucleotides as therapeutic agents)
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
DK0677056T3 (da) Oligonukleotid-alkylphosphonater og -alkylphosphonothioater
MX9406552A (es) Metodo, composiciones y dispositivos para la admi nistracion de polinucleotidos desnudos que codifi can peptidos biologicamente activos.
KR960700062A (ko) 산성 pH에서의 안정성을 개선시키기 위해 변형된 올리고누클레오티드(OLIGONUCLEOTIDES MODIFIED TO IMPROVE STABILITY AT ACIC pH)
CA2457034A1 (en) Ophthalmic composition comprising an ascomycin
CA2377290A1 (en) Utilization of a highly fluorinated oligomeric alkane in ophthalmology
RS50046B (sr) Farmaceutske kompozicije tizoksanida i nitazoksanida
FR2790757B1 (fr) Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
CA2132265C (en) Anti-sense oligonucleotides against hsv-1, and their preparation
DK0414607T3 (da) Anti-sense oligonucleotidssekvenser, anti-mRNA mod alpha-TNF; deres fremstilling og anvendelse som lægemiddel samt farmaceutiske præparater med indhold deraf
HUP0002683A2 (hu) Terápiás anyagok sejtekhez való eljuttatásának fokozására szolgáló készítmények és módszerek
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
CA2174122A1 (en) Therapeutic delivery compositions and methods of use thereof
EP0739901A3 (en) Novel oligoribonucleotide derivatives and application thereof to antiviral agents
WO2005039480A8 (en) AChE ANTISENSE DEOXYOLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT
ZA889521B (en) Polystyrene polymers and their use as cholesterol lowering agents
WO2024019196A1 (ko) 핵산 분자, 핵산 구조체, 및 이를 포함하는 면역 증진용 조성물 및 후천성 면역결핍 증후군 치료용 약학 조성물